Choosing the Right Antifungal Agent in ICU Patients

Andrea Cortegiani, Jeanne Chatelon, Nadim Cassir, Emmanuelle Hammad, Jeanne Chatelon, Marc Leone

Risultato della ricerca: Article

6 Citazioni (Scopus)

Abstract

Fungi are responsible for around 20% of microbiologically documented infections in intensive care units (ICU). In the last decade, the incidence of invasive fungal infections (IFI), including candidemia, has increased steadily because of increased numbers of both immunocompromised and ICU patients. To improve the outcomes of patients with IFI, intensivists need to be aware of the inherent challenges. This narrative review summarizes the features of routinely used treatments directed against IFI in non-neutropenic ICU patients, which include three classes of antifungals: polyenes, azoles, and echinocandins. ICU patients' pathophysiological changes are responsible for deep changes in the pharmacokinetics of antifungals. Moreover, drug interactions affect the response to antifungal treatments. Consequently, appropriate antifungal dosage is a challenge under these special conditions. Dosages should be based on renal and liver function, and serum concentrations should be monitored. This review summarizes recent guidelines, focusing on bedside management.
Lingua originaleEnglish
pagine (da-a)3308-3320
Numero di pagine13
RivistaAdvances in Therapy
Volume36
Stato di pubblicazionePublished - 2019

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)

Fingerprint Entra nei temi di ricerca di 'Choosing the Right Antifungal Agent in ICU Patients'. Insieme formano una fingerprint unica.

  • Cita questo

    Cortegiani, A., Chatelon, J., Cassir, N., Hammad, E., Chatelon, J., & Leone, M. (2019). Choosing the Right Antifungal Agent in ICU Patients. Advances in Therapy, 36, 3308-3320.